Literature DB >> 26057950

Formation Mechanism of Coamorphous Drug-Amino Acid Mixtures.

Katrine Tarp Jensen1, Flemming Hofmann Larsen1, Claus Cornett1, Korbinian Löbmann1, Holger Grohganz1, Thomas Rades1.   

Abstract

Two coamorphous drug-amino acid systems, indomethacin-tryptophan (Ind-Trp) and furosemide-tryptophan (Fur-Trp), were analyzed toward their ease of amorphization and mechanism of coamorphization during ball milling. The two mixtures were compared to the corresponding amorphization of the pure drug without amino acid. Powder blends at a 1:1 molar ratio were milled for varying times, and their physicochemical properties were investigated using XRPD, (13)C solid state NMR (ssNMR), and DSC. Comilling the drug with the amino acid reduced the milling time required to obtain an amorphous powder from more than 90 min in the case of the pure drugs to 30 min for the coamorphous powders. Amorphization was observed as reductions in XRPD reflections and was additionally quantified based on normalized principal component analysis (PCA) scores of the ssNMR spectra. Furthermore, the evolution in the glass temperature (Tg) of the coamorphous systems over time indicated complete coamorphization after 30 min of milling. Based on the DSC data it was possible to identify the formation mechanism of the two coamorphous systems. The Tg position of the samples suggested that coamorphous Ind-Trp was formed by the amino acid being dissolved in the amorphous drug, whereas coamorphous Fur-Trp was formed by the drug being dissolved in the amorphous amino acid.

Entities:  

Keywords:  amorphization; coamorphous; drug−amino acid; furosemide; indomethacin

Mesh:

Substances:

Year:  2015        PMID: 26057950     DOI: 10.1021/acs.molpharmaceut.5b00295

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  7 in total

1.  Melt Extrusion of High-Dose Co-Amorphous Drug-Drug Combinations : Theme: Formulation and Manufacturing of Solid Dosage Forms Guest Editors: Tony Zhou and Tonglei Li.

Authors:  Lærke Arnfast; Md Kamruzzaman; Korbinian Löbmann; Johanna Aho; Stefania Baldursdottir; Thomas Rades; Jukka Rantanen
Journal:  Pharm Res       Date:  2017-09-19       Impact factor: 4.200

Review 2.  Co-amorphous Drug Delivery Systems: a Review of Physical Stability, In Vitro and In Vivo Performance.

Authors:  Qin Shi; Yanan Wang; Sakib M Moinuddin; Xiaodong Feng; Fakhrul Ahsan
Journal:  AAPS PharmSciTech       Date:  2022-09-19       Impact factor: 4.026

3.  Physico-Chemical Properties, Aerosolization and Dissolution of Co-Spray Dried Azithromycin Particles with L-Leucine for Inhalation.

Authors:  Sharad Mangal; Haichen Nie; Rongkun Xu; Rui Guo; Alex Cavallaro; Dmitry Zemlyanov; Qi Tony Zhou
Journal:  Pharm Res       Date:  2018-01-08       Impact factor: 4.200

Review 4.  Co-Amorphous Solid Dispersions for Solubility and Absorption Improvement of Drugs: Composition, Preparation, Characterization and Formulations for Oral Delivery.

Authors:  Anna Karagianni; Kyriakos Kachrimanis; Ioannis Nikolakakis
Journal:  Pharmaceutics       Date:  2018-07-19       Impact factor: 6.321

5.  Co-amorphous solid dispersion systems of lacidipine-spironolactone with improved dissolution rate and enhanced physical stability.

Authors:  Zhaomeng Wang; Mengchi Sun; Tian Liu; Zisen Gao; Qing Ye; Xiao Tan; Yanxian Hou; Jin Sun; Dun Wang; Zhonggui He
Journal:  Asian J Pharm Sci       Date:  2018-11-14       Impact factor: 6.598

6.  Combining Co-Amorphous-Based Spray Drying with Inert Carriers to Achieve Improved Bioavailability and Excellent Downstream Manufacturability.

Authors:  Yingxi Zhang; Yuan Gao; Xiaoxiao Du; Rou Guan; Zhonggui He; Hongzhuo Liu
Journal:  Pharmaceutics       Date:  2020-11-08       Impact factor: 6.321

7.  Co-Amorphous Screening for the Solubility Enhancement of Poorly Water-Soluble Mirabegron and Investigation of Their Intermolecular Interactions and Dissolution Behaviors.

Authors:  Ji-Hun An; Changjin Lim; Alice Nguvoko Kiyonga; In Hwa Chung; In Kyu Lee; Kilwoong Mo; Minho Park; Wonno Youn; Won Rak Choi; Young-Ger Suh; Kiwon Jung
Journal:  Pharmaceutics       Date:  2018-09-05       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.